Oligonucleotide sensitizes A375 cells to cisplatin

Mei Wang,Xiaoli Wang,Bing Wang,Shengshun Tan
DOI: https://doi.org/10.3969/j.issn.1671-8259.2007.06.011
2007-01-01
Abstract:Objective: To investigate whether targeting survivin has the potential to sensitize A375 cells to chemotherapy. Methods: By trypan blue exclusion assays we observed A375 cell proliferation inhibition induced by survivin antisense oligonucleotide (ASODN) and cisplatin. Results: A375 cells treated with a combination of 5 μmol/L ASODN and 0.5 mg/L cisplatin, and approximately 61.3% of the cells showed signs of cell death 72 h after the start of transfection trypan blue exclusion assays. Compared to treatments with either oligonucleotide or cisplatin alone, there were significant differences among the groups (P < 0.001). Cells were pre-treated 24 h with 5 μmol/L ASODN before combination treatment, and 68.0% of the cells showed signs of cell death, but there were not significant differences between combination treated group and pre-treated group. Conclusion: A combination treatment with ASODN and cisplatin possesses synergy in inhibiting A375 cell proliferation, indicating that oligonucleotide sensitizes A375 cells to cisplatin therapy.
What problem does this paper attempt to address?